Drugs that contain Betamethasone Dipropionate; Calcipotriene
1. List of Enstilar drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10688108 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10660908 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US9566286 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10716799 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US9119781 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10617698 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10130640 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
| US10682364 | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamind D analogue and a corticosteroid |
Jun, 2031
(8 years from now) | |
|
US10130640
(Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
|
US9119781
(Pediatric) | LEO PHARMA AS | Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid |
Dec, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity (PED) | Jan 30, 2023 |
Market Authorisation Date: 16 October, 2015
Treatment: Topical treatment of plaque psoriasis in patients 12 years and older; Plaque psoriasis
Dosage: AEROSOL, FOAM;TOPICAL
ENSTILAR family patents
12
United States
3
Japan
2
Korea, Republic of
2
Israel
2
Denmark
2
European Union
1
Portugal
1
Singapore
1
Malaysia
1
Russia
1
Spain
1
Brazil
1
Croatia
1
New Zealand
1
Mexico
1
China
1
Hong Kong
1
South Africa
1
Canada
1
Cyprus
1
Slovenia
1
Ukraine
1
Poland
1
Australia
1
RS
2. List of Wynzora drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265265 | MC2 | Topical composition |
Sep, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Dosage Form (NDF) | Jul 20, 2023 |
Market Authorisation Date: 20 July, 2020
Treatment: NA
Dosage: CREAM;TOPICAL
WYNZORA family patents
3
United States
2
United Kingdom
2
China
2
European Union
1
Taiwan, Province of China
1
Japan
1
Australia
1
Denmark
1
Russia
1
Canada
1
Argentina
1
South Africa
1
Spain
1
Austria
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic